2411526-47-9
2411526-47-9
Chemical Structure
Sotevtamab
Synonym(s): 16B5; AB-16B5
- CAS No.: 2411526-47-9
- Formula:N/A
- Molecular Weight:(146.2 kDa)
SMILES: [Sotevtamab]
Biological Activity: Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sotevtamab | 99.67% | Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467.
- [2]. Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098.
- [3]. Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.
